Hsbc Holdings PLC Buys Shares of 158,889 Halozyme Therapeutics, Inc. $HALO

Hsbc Holdings PLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 158,889 shares of the biopharmaceutical company’s stock, valued at approximately $12,447,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of HALO. MidFirst Bank purchased a new stake in Halozyme Therapeutics during the second quarter valued at $27,000. Larson Financial Group LLC boosted its position in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Halozyme Therapeutics in the second quarter worth about $28,000. Measured Wealth Private Client Group LLC grew its stake in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the period. Finally, Quantbot Technologies LP bought a new stake in Halozyme Therapeutics during the second quarter valued at approximately $30,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $105.35 on Friday. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $109.66. The business has a 50 day simple moving average of $87.01 and a two-hundred day simple moving average of $74.78. The stock has a market capitalization of $11.96 billion, a PE ratio of 31.45, a P/E/G ratio of 0.43 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $79,987,320.40. This trade represents a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 64,103 shares of company stock worth $5,226,496. Insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

HALO has been the topic of several recent research reports. Citizens Jmp increased their price target on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. UBS Group reissued a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. HC Wainwright upped their price objective on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. TD Cowen raised their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.